Weight loss drug will be easier to access as Eli Lilly disrupts the pharmacy model - ABC listen
Eli Lilly launched an online platform to dispense and deliver tirzepatide, a weight loss drug, after failing to get it listed on the PBS. The platform, already in the US and UK, will offer home delivery via a third-party pharmacy. Fiji declared a national emergency over its HIV crisis, and Australia's TGA removed Andrographis from approved medicine ingredients due to adverse reactions.
How this was made
The 30-second read
Why it matters
The move may improve patient access and create a new revenue stream, but success depends on consumer uptake and regulatory approval.
Market read
Introduces a novel distribution channel for a high‑growth weight‑loss drug, potentially influencing competitor strategies.
What to watch
Potential pushback from traditional pharmacy networks and insurance reimbursement complexities.
Background
Eli Lilly's tirzepatide failed to secure PBS listing in Australia, prompting a new online dispensing approach.
Ticker impact
Eli Lilly launched an online platform to dispense its GLP‑1 drug tirzepatide after PBS listing failure.
LLY may see modest upside as the new distribution channel expands access.
First‑time launch of a direct‑to‑consumer model for tirzepatide could boost volumes, but execution risk remains.
Market effects
May pressure other GLP‑1 manufacturers to consider similar distribution models.
Australia's PBS decision could affect local pricing dynamics.
Highlights shift toward online pharma distribution globally.
Counterpoint
The platform could face regulatory hurdles and limited adoption, dampening impact.
Key entities
- CompanyEli Lilly
Pharmaceutical manufacturer launching the online platform.
- RegulatorPBS
Australian Pharmaceutical Benefits Scheme that denied listing.
